Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Beijer Byggmaterial in connection with entering into an agreement to acquire Karl Ekesiöö Bygghandel
Mandate

Vinge has advised Beijer Byggmaterial in connection with entering into an agreement to acquire Karl Ekesiöö Bygghandel

June 25, 2019 M&A

Vinge has advised Beijer Byggmaterial AB (“Beijer Byggmaterial”) in connection with Beijer Byggmaterial entering into an agreement to acquire Karl Ekesiöö Bygghandel AB. Completion of the transaction is subject to customary conditions.

Karl Ekesiöö Bygghandel AB is operating two branches in attractive locations with substantial building activity in the metro-area of Stockholm, (where Beijer Byggmaterial earlier this year acquired the business of Bygg-Ole).

Beijer Byggmaterial is part of Stark Group, the largest retailer and distributor of building materials in the Nordic region with operations in Denmark, Greenland, Norway, Sweden and Finland.

Vinge’s team consisted of, among others, Jonas Bergström, Linda Sengul, Anna Thoms,  Desirée Sjöblom and Jesper Lindvall (M&A), Agnes Perbo (Corporate Commercial), Kristoffer Larsson (Real Property/Lease Agreements) and Sophia Holm (Employment).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024